Dr. Reddy's Laboratories (DRREDDY) Stock Overview
Operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
DRREDDY Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Dr. Reddy's Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,226.20 |
| 52 Week High | ₹1,405.90 |
| 52 Week Low | ₹1,020.00 |
| Beta | 0.36 |
| 1 Month Change | -4.47% |
| 3 Month Change | -2.93% |
| 1 Year Change | 1.40% |
| 3 Year Change | 39.28% |
| 5 Year Change | 26.96% |
| Change since IPO | 1,275.82% |
Recent News & Updates
Benign Growth For Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Underpins Its Share Price
Nov 21
Here's Why Dr. Reddy's Laboratories (NSE:DRREDDY) Has Caught The Eye Of Investors
Oct 31Recent updates
Benign Growth For Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Underpins Its Share Price
Nov 21Here's Why Dr. Reddy's Laboratories (NSE:DRREDDY) Has Caught The Eye Of Investors
Oct 31Earnings Working Against Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Share Price
Aug 22Earnings Miss: Dr. Reddy's Laboratories Limited Missed EPS By 17% And Analysts Are Revising Their Forecasts
Jul 26The Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Yearly Results Are Out And Analysts Have Published New Forecasts
May 13Is Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Trading At A 20% Discount?
Apr 10Does Dr. Reddy's Laboratories (NSE:DRREDDY) Have A Healthy Balance Sheet?
Mar 02Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Prospects Need A Boost To Lift Shares
Feb 12With EPS Growth And More, Dr. Reddy's Laboratories (NSE:DRREDDY) Makes An Interesting Case
Dec 27Shareholder Returns
| DRREDDY | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.5% | -0.9% | -0.7% |
| 1Y | 1.4% | -1.4% | 4.2% |
Return vs Industry: DRREDDY exceeded the Indian Pharmaceuticals industry which returned -1.4% over the past year.
Return vs Market: DRREDDY underperformed the Indian Market which returned 4.2% over the past year.
Price Volatility
| DRREDDY volatility | |
|---|---|
| DRREDDY Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.5% |
| 10% least volatile stocks in IN Market | 3.1% |
Stable Share Price: DRREDDY has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: DRREDDY's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 27,811 | Erez Israeli | www.drreddys.com |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Dr. Reddy's Laboratories Limited Fundamentals Summary
| DRREDDY fundamental statistics | |
|---|---|
| Market cap | ₹1.02t |
| Earnings (TTM) | ₹58.62b |
| Revenue (TTM) | ₹342.15b |
Is DRREDDY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DRREDDY income statement (TTM) | |
|---|---|
| Revenue | ₹342.15b |
| Cost of Revenue | ₹149.07b |
| Gross Profit | ₹193.08b |
| Other Expenses | ₹134.46b |
| Earnings | ₹58.62b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 70.41 |
| Gross Margin | 56.43% |
| Net Profit Margin | 17.13% |
| Debt/Equity Ratio | 12.4% |
How did DRREDDY perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/24 22:22 |
| End of Day Share Price | 2025/11/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dr. Reddy's Laboratories Limited is covered by 77 analysts. 38 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| Ashwin Mehta | Ambit Capital |